Psychometric validation of the Portuguese version of the Neuropathic Pain Symptoms Inventory

Daniel Ciampi de Andrade, Karine A S L Ferreira, Carine M Nishimura, Lyn T Yeng, Abrahão F Batista, Katia de Sá, Joaci Araujo, Patrick R N A G Stump, Helena H Kaziyama, Ricardo Galhardoni, Erich T Fonoff, Gerson Ballester, Telma Zakka, Didier Bouhassira, Manoel J Teixeira, Daniel Ciampi de Andrade, Karine A S L Ferreira, Carine M Nishimura, Lyn T Yeng, Abrahão F Batista, Katia de Sá, Joaci Araujo, Patrick R N A G Stump, Helena H Kaziyama, Ricardo Galhardoni, Erich T Fonoff, Gerson Ballester, Telma Zakka, Didier Bouhassira, Manoel J Teixeira

Abstract

Background: It has been shown that different symptoms or symptom combinations of neuropathic pain (NeP) may correspond to different mechanistic backgrounds and respond differently to treatment. The Neuropathic Pain Symptom Inventory (NPSI) is able to detect distinct clusters of symptoms (i.e. dimensions) with a putative common mechanistic background. The present study described the psychometric validation of the Portuguese version (PV) of the NPSI.

Methods: Patients were seen in two consecutive visits, three to four weeks apart. They were asked to: (i) rate their mean pain intensity in the last 24 hours on an 11-point (0-10) numerical scale; (ii) complete the PV-NPSI; (iii) provide the list of pain medications and doses currently in use. VAS and Global Impression of Change (GIC) were filled out in the second visit.

Results: PV-NPSI underwent test-retest reliability, factor analysis, analysis of sensitivity to changes between both visits. The PV-NPSI was reliable in this setting, with a good intra-class correlation for all items. The factorial analysis showed that the PV-NPSI inventory assessed different components of neuropathic pain. Five different factors were found. The PV-NPSI was adequate to evaluate patients with neuropathic pain and to detect clusters of NeP symptoms.

Conclusions: The psychometric properties of the PV-NPSI rendered it adequate to evaluate patients with both central and peripheral neuropathic pain syndromes and to detect clusters of NeP symptoms.

© 2011 de Andrade et al; licensee BioMed Central Ltd.

Figures

Figure 1
Figure 1
Correlation between the GIC-p scores at the second visit and the change in the PV-NPSI score between the two visits (PV-NPSI visit 2 - PV-NPSI visit 1) (rho = 0.727).

References

    1. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92(1-2):147–157. doi: 10.1016/S0304-3959(00)00482-6.
    1. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380–387. doi: 10.1016/j.pain.2007.08.013.
    1. Martinez V, Fletcher D, Martin F, Orlikowski D, Sharshar T, Chauvin M, Bouhassira D, Attal N. Small fibre impairment predicts neuropathic pain in Guillain-Barre syndrome. Pain. 2010;151(1):53–60. doi: 10.1016/j.pain.2010.05.017.
    1. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain. 2006;22(1):97–103. doi: 10.1097/01.ajp.0000173018.64741.62.
    1. Kaki AM, El-Yaski AZ, Youseif E. Identifying neuropathic pain among patients with chronic low-back pain: use of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. Reg Anesth Pain Med. 2005;30(5):422–428.
    1. Martinez V, Fletcher D, Bouhassira D, Sessler DI, Chauvin M. The evolution of primary hyperalgesia in orthopedic surgery: quantitative sensory testing and clinical evaluation before and after total knee arthroplasty. Anesth Analg. 2007;105(3):815–821. doi: 10.1213/01.ane.0000278091.29062.63.
    1. Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI. Neuropathic Pain Features in Patients With Bone Metastases Referred for Palliative Radiotherapy. J Clin Oncol. 2010.
    1. Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepere C, Rougier P, Guirimand F. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144(3):245–252. doi: 10.1016/j.pain.2009.03.024.
    1. de Andrade DC, Jean S, Clavelou P, Dallel R, Bouhassira D. Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness. BMC Infect Dis. 2010;10:31. doi: 10.1186/1471-2334-10-31.
    1. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain. 2008;138(2):343–353. doi: 10.1016/j.pain.2008.01.006.
    1. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology. 2002;58(4):554–563.
    1. Attal N, Gaude V, Brasseur L, Dupuy M, Guirimand F, Parker F, Bouhassira D. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54(3):564–574.
    1. Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol. 1998;40(4):191–200. doi: 10.1159/000007979.
    1. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48(2):332–338.
    1. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J. et al.Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108(3):248–257. doi: 10.1016/j.pain.2003.12.024.
    1. Crawford B, Bouhassira D, Wong A, Dukes E. Conceptual adequacy of the neuropathic pain symptom inventory in six countries. Health Qual Life Outcomes. 2008;6:62. doi: 10.1186/1477-7525-6-62.
    1. Gordon RG. , Jr. Portuguese. Ethnologue: Languages of the World. 15. Vol. 1. SIL International; 2005.
    1. Padua L, Briani C, Jann S, Nobile-Orazio E, Pazzaglia C, Morini A, Mondelli M, Ciaramitaro P, Cavaletti G, Cocito D. et al.Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol Sci. 2009;30(2):99–106. doi: 10.1007/s10072-009-0025-y.
    1. Villoria J, Rodríguez M, Berro MJ, Stern A, Sánchez-Magro I. Psychometric Validation of the neuropathic pain symptom inventory for its use in Spanish. J Pain Symptom Manage. 2011;42(1):134–46. doi: 10.1016/j.jpainsymman.2010.09.018.
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635. doi: 10.1212/01.wnl.0000282763.29778.59.
    1. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252(14):1905–1907. doi: 10.1001/jama.1984.03350140051025.
    1. Simons DG. Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. J Electromyogr Kinesiol. 2004;14(1):95–107. doi: 10.1016/j.jelekin.2003.09.018.
    1. Justins DM. Complex Regional Pain Syndrome. Seattle: IASP Scientific Program Committee (11th World Congress on Pain); 2005.
    1. Masters Steedman S, Middaugh SJ, Kee WG, Carson DS, Harden RN, Miller MC. Chronic-pain medications: equivalence levels and method of quantifying usage. Clin J Pain. 1992;8(3):204–214. doi: 10.1097/00002508-199209000-00004.
    1. Kachigan SK. Multivariate statistical analysis: a conceptual introduction. 2. New york: Radius Press; 1991.
    1. Muller R, Buttner P. A critical discussion of intraclass correlation coefficients. Stat Med. 1994;13(23-24):2465–2476. doi: 10.1002/sim.4780132310.
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281–289. doi: 10.1016/j.jpain.2005.11.008.
    1. Potter J, Higginson IJ, Scadding JW, Quigley C. Identifying neuropathic pain in patients with head and neck cancer: use of the Leeds Assessment of Neuropathic Symptoms and Signs Scale. J R Soc Med. 2003;96(8):379–383. doi: 10.1258/jrsm.96.8.379.
    1. Perez C, Galvez R, Insausti J, Bennett M, Ruiz M, Rejas J. [Linguistic adaptation and Spanish validation of the LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) scale for the diagnosis of neuropathic pain] Med Clin (Barc) 2006;127(13):485–491. doi: 10.1157/13093266.
    1. Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M. Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain. 2004;5(8):427–432. doi: 10.1016/j.jpain.2004.07.001.
    1. Santos JG, Brito JO, Andrade DCd, Kaziyama VM, Ferreira KA, Souza I, Teixeira MJ, Bouhassira D, Baptista AF. Translation to Portuguese and Validation of the Douleur Neuropathique 4 Questionnaire. The Journal of Pain. 2010;11(5):484–490. doi: 10.1016/j.jpain.2009.09.014.
    1. Truini A, Biasiotta A, La Cesa S, Di Stefano G, Galeotti F, Petrucci MT, Inghilleri M, Cartoni C, Pergolini M, Cruccu G. Mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. Pain. 2010;150(3):516–521. doi: 10.1016/j.pain.2010.06.006.
    1. Hatem SM, Attal N, Ducreux D, Gautron M, Parker F, Plaghki L, Bouhassira D. Clinical, functional and structural determinants of central pain in syringomyelia. Brain. 2010;133(11):3409–3422. doi: 10.1093/brain/awq244.
    1. Eisenberg E, Midbari A, Haddad M, Pud D. Predicting the analgesic effect to oxycodone by 'static' and 'dynamic' quantitative sensory testing in healthy subjects. Pain. 2010;151(1):104–109. doi: 10.1016/j.pain.2010.06.025.
    1. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96(3):375–383. doi: 10.1016/S0304-3959(01)00484-5.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere